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England and the USA. Lancet 2014;383:963-9.EDITORS’ COMMENTARYThomas L. Forbes, MD, and A. Ross Naylor, MBChB, MD, FRCS, Toronto, Ontario, Canada; and Leicester,
United KingdomThe evidence for reducing the diameter threshold for elective
intervention in asymptomatic women with an abdominal aortic
aneurysm (AAA) to 5.0 cm is: (1) women have signiﬁcantly nar-
rower aortas (compared with men), so that the diameter of an
AAA requiring intervention should be smaller; (2) comorbidities
(risks) increase with age, meaning it is better to intervene at an
earlier age (size) to reduce operative mortality; (3) if rupture oc-
curs, women face higher mortality rates than men; and (5) data
from randomized and nonrandomized studies suggest that AAAs
in women rupture at slightly smaller diameters than in men
(5.0 cm). Advocates for reducing the diameter threshold to
5 cm concede that women incur higher perioperative mortality
rates (compared with men), but that mortality rates after elective
open repair (OR) or endovascular aneurysm repair (EVAR) are
several magnitudes lower than the mortality associated with the
treatment of a ruptured AAA.
Advocates for leaving diameter thresholds unchanged argue
that although some of the points raised above have evidential sup-
port, there are important confounding issues relating to (1)
women being under-represented in the trials, which were never
powered to perform subgroup analyses regarding gender; (2)
data suggesting that women may be rupturing at slightly smaller
aortic diameters are statistically weak (small number of events in
a small number of patients) and might represent a type II statistical
error, and (3) even if women did rupture at slightly smaller aortic
diameters, any potential beneﬁt through early intervention would
be negated by the twofold excess mortality rate after elective
EVAR or OR.So which side wins? One (undiscussed) issue remains the his-
torical selection of 5.5 cm as the diameter threshold for intervening
in the ﬁrst place. The choice of 5.5 cm was not based on science
but upon the equipoise of those surgeons who were prepared to
randomize patients with 5-cm, 5.5-cm, or 6.0-cm AAAs. At the
time, the consensus was 5.5 cm, but this “one size ﬁts all” mea-
surement was never designed to deliver optimal diameter thresh-
olds for men as opposed to women. Moreover, because some
European and United States guidelines now tacitly support
“consideration” for elective interventions in women with 5.0-cm
to 5.5-cm AAAs, the vox populi interpretation is likely to be that
this is reasonable.
There are, however, important caveats for those surgeons and
interventionists who advocate elective interventions in female pa-
tients with 5.0-cm AAAs:
First, they need to be very clear about which diameter
measurement method they are using. Those measuring inner-to-
inner AAA diameter using ultrasound imaging will document
diameters 4 mm to 5 mm less than if the outer-to-outer measure-
ment method is used. If, however, computed tomography is used
to measure an outer-to-outer diameter, this will then be 4 mm to
5 mm greater than the corresponding ultrasound measurement
and up to 1 cm greater than any inner-to-inner ultrasound-derived
measurement.
Second, and at the very least, there should be no talk of “time
bombs” during the consent process, and female patients with 5-cm
AAAs under consideration for surgery need to be informed about
the underlying controversy. Put simply, there should be no rush
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Like it or not, they do face a higher morbidity and mortality
than men, and it is incumbent on the treating clinician to ensure
that a very careful risk assessment has been performed, whether
comorbidities can be optimized, and even whether he or she
may be the best person to undertake any planned intervention.
Finally, although we can all hope that industry comes up with
better endovascular technologies to enable a greater proportion
of female patients to undergo EVAR (which they will), there isa very real risk that “bending the rules” to offer elective EVAR
to female patients with 5-cm AAAs outside the manufacturer’s in-
dications for use can be deleterious to the patient (who faces a
higher risk of endoleak and late conversion) and possibly the
treating clinician. Surgeons and interventionists should be aware
that in many countries, if they perform an EVAR outside the
manufacturer’s indications for use, they absolve the stent
manufacturing company from any future medicolegal responsibil-
ity and assume this themselves.
